Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model-Reference-Cited by-同舟云学术

Dabrafenib protects from cisplatin-induced hearing loss in a clinically relevant mouse model

Published:2023-12-22 Issue:24 Volume:8 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Ingersoll Matthew A.,Lutze Richard D.,Pushpan Chithra K.,Kelmann Regina G.,Liu Huizhan^ORCID,May Mark T.^ORCID,Hunter William J.,He David Z.Z.^ORCID,Teitz Tal^ORCID

Funder

National Institutes of Health

American Hearing Research Foundation

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/171140/files/pdf

Reference82 articles.

1. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss

2. Cisplatin in cancer therapy: Molecular mechanisms of action

3. Review: Ototoxic Characteristics of Platinum Antitumor Drugs

4. Mechanisms of Aminoglycoside- and Cisplatin-Induced Ototoxicity

5. Cisplatin is retained in the cochlea indefinitely following chemotherapy

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oseltamivir (Tamiflu), a commonly prescribed antiviral drug, mitigates hearing loss in mice;Clinical and Translational Medicine;2024-08

2. Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss;Pharmaceuticals;2024-06-05

3. FDA-Approved MEK1/2 Inhibitor, Trametinib, Protects Mice from Cisplatin and Noise-Induced Hearing Loss;2024-05-21

4. Oseltamivir (Tamiflu), a Commonly Prescribed Antiviral Drug, Mitigates Hearing Loss in Mice;2024-05-08

5. KSR1 knockout mouse model demonstrates MAPK pathway's key role in cisplatin- and noise-induced hearing loss;The Journal of Neuroscience;2024-03-28